CoChat

Finasteride therapy does not alter bone turnover in men with benign prostatic hyperplasia--a Clinical Research Center study

Tollin, S. R. · 1996 · Journal of Clinical Endocrinology & Metabolism
Cited by 32

The DOI matches its Crossref record; 2 of the 2 references it cites were found in a registry or an index.

Abstract

Benign prostatic hyperplasia is often treated with finasteride, which inhibits the conversion of testosterone to dihydrotestosterone (DHT). Aside from the prostate, other androgen-dependent tissues seem to be unaffected by selective DHT deficiency, but the effect on bone density in humans has not yet been defined. To study this question, we compared indices of bone turnover and bone mineral density in 35 men treated with finasteride with controls. Bone resorption was assessed by measuring urinary excretion of N-telopeptide cross-links of type I collagen and hydroxyproline, and bone formation was assessed by measuring serum osteoncalcin and bone-specific alkaline phosphatase. Bone density of the spine and hip were assessed by dual energy x-ray absorptiometry. We found that finasteride-treated patients had mean DHT levels 81% lower than controls (P < 0.0001). There were no significant differences between the two groups in any of the markers of bone turnover or measures of bone density. These results suggest that testosterone can maintain bone density in men even in the absence of DHT. Although long term studies are needed, our results suggest that men who take finasteride are not at increased risk for bone loss.

Overview

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1210/jc.81.3.1031

Cites

2 of 2 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 2 references

Cited by

  • Androgens and Bone

    Vanderschueren, D., Vandenput, L., Boonen, S., Lindberg, M. K., Bouillon, R., & Ohlsson, C. (2004) · Endocrine Reviews · doi:10.1210/er.2003-0003 · Cited by 717

    “Finasteride, a type II 5 -reductase inhibitor, does not decrease vertebral bone density (388) or increase bone turnover markers (35) in men suffering from benign prostate hyperplasia, according to two small-sized short-term studies.”
    Background
  • Exogenous Testosterone or Testosterone with Finasteride Increases Bone Mineral Density in Older Men with Low Serum Testosterone

    Amory, J. K., Watts, N. B., Easley, K. A., Sutton, P. R., Anawalt, B. D., Matsumoto, A. M., Bremner, W. J., & Tenover, J. L. (2004) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2003-031110 · Cited by 475

    “Forty men who passed initial screening were not enrolled for the following reasons: abnormal PSA, prostate ultrasound, postvoid residual, or symptom score (11); pituitary, thyroid, or adrenal disease (5); medical illness (4); second T levels above 350 ng/dl (4); total cholesterol above 300 mg/dl (1); or being eligible…”
    Background
  • Serum androgen levels in black, Hispanic, and white men

    Litman, H. J., Bhasin, S., Link, C. L., Araujo, A. B., & McKinlay, J. B. (2006) · The Journal of Clinical Endocrinology & Metabolism · doi:10.1210/jc.2006-0037 · Cited by 127

    “Furthermore, men treated with SRD5A2 inhibitors for the treatment of benign prostatic hyperplasia do not experience loss of skeletal muscle mass or bone mineral density, suggesting that 5 -reduction of testosterone to DHT is not obligatory for mediating its anabolic effects on the muscle and the bone (56).”
    Background

See all 32

Metadata

Authors
Tollin, S. R.
Venue
Journal of Clinical Endocrinology & Metabolism
Published
1996-03-01
Volume
81
Issue
3
Pages
1031-1034
ISSN
0021-972X (ISSN-L)
OpenAlex
W1981157079
Cited by
32
References
2
FWCI
2.84
Type
journal article
Language
en
Open access
closed

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Finasteride therapy does not alter bone turnover in men with benign prostatic hyperplasia--a Clinical Research Center study. https://app.cochat.ai/papers/10.1210/jc.81.3.1031
The paper
Tollin, S. R. (1996). Finasteride therapy does not alter bone turnover in men with benign prostatic hyperplasia--a Clinical Research Center study. Journal of Clinical Endocrinology & Metabolism. https://doi.org/10.1210/jc.81.3.1031

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.